Isdn Stada

Isosorbide dinitrate, the active ingredient in Isdn Stada, is an organic nitrate presented as an oral dosage form for systemic use. It is employed to relieve angina pectoris and to manage chronic heart failure by reducing cardiac workload. The medication works by releasing nitric oxide, which dilates blood vessels and lowers both preload and afterload.

GNH USA supplies Isdn Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isosorbide dinitrate is used in the management of cardiovascular conditions that involve myocardial oxygen demand.

Angina pectoris: reduces the frequency and severity of chest pain by decreasing myocardial oxygen demand. Chronic heart failure: improves symptoms and exercise capacity by lowering cardiac preload and afterload. Stable angina prophylaxis: helps prevent angina attacks during physical exertion. Ischemic heart disease: alleviates ischemic episodes by enhancing coronary blood flow. Heart failure with reduced ejection fraction: supports standard therapy by improving hemodynamics.

Isosorbide dinitrate may cause a range of adverse reactions, most of which are dose‑related and transient.

Common Side Effects: - Headache: throbbing pain often occurring shortly after dosing. - Dizziness or light‑headedness: related to blood pressure changes. - Flushing: warm sensation and reddening of the skin. - Hypotension: measurable drop in blood pressure, especially when standing. - Tachycardia: compensatory increase in heart rate. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Syncope: fainting episodes due to inadequate cerebral perfusion. - Myocardial infarction: rare but possible if coronary perfusion is compromised. - Allergic reaction: rash, itching, or swelling indicating hypersensitivity. - Methemoglobinemia: rare blood disorder causing reduced oxygen delivery.

When prescribing isosorbide dinitrate, clinicians should consider several safety measures.

Dose titration: start with the lowest effective dose and increase gradually under medical supervision. Avoid concurrent use with PDE‑5 inhibitors: combined use may cause profound hypotension. Monitor blood pressure: regular checks to detect excessive falls. Use with caution in anemia or hypovolemia: patients may be more susceptible to hypotensive effects. Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Isosorbide dinitrate can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): risk of severe hypotension. - Other organic nitrates (e.g., nitroglycerin): additive vasodilatory effect. - Strong antihypertensives (e.g., hydralazine): may cause excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - Beta‑blockers and ACE inhibitors: monitor for additive blood pressure lowering. - Diuretics: watch for volume depletion and orthostatic hypotension. - Azole antifungals (e.g., ketoconazole): may increase nitrate plasma levels.